US Patent

US11504334 — Synthetic progestogens and pharmaceutical compositions comprising the same

Formulation · Assigned to Laboratorios Leon Farma SA · Expires 2031-06-28 · 5y remaining

Vulnerability score 56/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects synthetic progestogens, such as 6Î²,7Î²:15Î²,16Î²-Dimethylene-3-oxo-17Î±-pregn-4-ene-21,17-carbolactone, and pharmaceutical compositions containing them.

USPTO Abstract

Described herein are synthetic progestogens, such as 6Î²,7Î²:15Î²,16Î²-Dimethylene-3-oxo-17Î±-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.

Drugs covered by this patent

Slynd (DROSPIRENONE) · Exeltis Usa Inc

Patent Metadata

Patent number: US11504334
Jurisdiction: US
Classification: Formulation
Expires: 2031-06-28
Drug substance claim: No
Drug product claim: Yes
Assignee: Laboratorios Leon Farma SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.